Lartesertib

CAS No. 2495096-26-7

Lartesertib( —— )

Catalog No. M35661 CAS No. 2495096-26-7

Lartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 201 Get Quote
5MG 312 Get Quote
10MG 534 Get Quote
25MG 1003 Get Quote
50MG 1674 Get Quote
100MG 2538 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Lartesertib
  • Note
    Research use only, not for human use.
  • Brief Description
    Lartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.
  • Description
    Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    ATM/ATR
  • Recptor
    ATM/ATR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2495096-26-7
  • Formula Weight
    448.45
  • Molecular Formula
    C23H21FN6O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (222.99 mM)
  • SMILES
    COc1cncc(F)c1-n1c2c(cnc3cc(OC)c(cc23)-c2cn(C)nc2C)n(C)c1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Alessandra AMBRUOSI, et al. Pharmaceutical preparation. WO2022058351A1.
molnova catalog
related products
  • KU-60019 (b)

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays.

  • KU-55933

    KU-55933 is a potent, specific, ATP-competitive inhibitor of ATM with Ki/IC50 of 2.2/13 nM.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, and is a potent, specific inhibitor of ATM kinase with IC50 of 6.3 nM, 270- and 1,600-fold selectivity over DNA-PKcs and ATR.